Biovista receives grant for R&D in personalized medicine

Biovista expects to utilize its Clinical Outcomes Search Space (COSS) platform and multi-dimensional profiling capabilities to identify new treatments that reflect patients’ individual pathophysiological characteristics.

The ‘p-medicine’ project is a four-year, EUR13.3m co-funded effort under the European Community’s 7th Framework Program that aims to develop new tools, infrastructure and VPH (Virtual Physiological Human) models in order to help accelerate the emergence of personalized medicine.

Biovista CEO Andreas Persidis said they are confident that their drug repositioning expertise combined with clinical and related data that will be easily integrated and interchangeable via the p-medicine infrastructure can move us in the right direction.